- Home
- KPLT vs CVKD Comparison
KPLT vs CVKD Comparison
Compare KPLT & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPLT
- CVKD
- Stock Information
- Founded
- KPLT 2012
- CVKD 2022
- Country
- KPLT United States
- CVKD United States
- Employees
- KPLT N/A
- CVKD N/A
- Industry
- KPLT Diversified Commercial Services
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- KPLT Consumer Discretionary
- CVKD Health Care
- Exchange
- KPLT Nasdaq
- CVKD Nasdaq
- Market Cap
- KPLT 35.6M
- CVKD 29.5M
- IPO Year
- KPLT N/A
- CVKD 2023
- Fundamental
- Price
- KPLT $7.95
- CVKD $10.28
- Analyst Decision
- KPLT Hold
- CVKD Strong Buy
- Analyst Count
- KPLT 2
- CVKD 1
- Target Price
- KPLT $12.00
- CVKD $32.00
- AVG Volume (30 Days)
- KPLT 20.0K
- CVKD 23.0K
- Earning Date
- KPLT 08-13-2025
- CVKD 08-06-2025
- Dividend Yield
- KPLT N/A
- CVKD N/A
- EPS Growth
- KPLT N/A
- CVKD N/A
- EPS
- KPLT N/A
- CVKD N/A
- Revenue
- KPLT $254,079,000.00
- CVKD N/A
- Revenue This Year
- KPLT $22.26
- CVKD N/A
- Revenue Next Year
- KPLT $11.03
- CVKD N/A
- P/E Ratio
- KPLT N/A
- CVKD N/A
- Revenue Growth
- KPLT 9.72
- CVKD N/A
- 52 Week Low
- KPLT $5.08
- CVKD $5.70
- 52 Week High
- KPLT $21.88
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- KPLT 44.59
- CVKD 24.53
- Support Level
- KPLT $7.30
- CVKD $10.00
- Resistance Level
- KPLT $10.09
- CVKD $13.30
- Average True Range (ATR)
- KPLT 0.93
- CVKD 0.89
- MACD
- KPLT -0.14
- CVKD -0.39
- Stochastic Oscillator
- KPLT 22.73
- CVKD 4.67
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.